Water Quality Standards for Biopharmaceutical Manufacturing

Water is the most widely used raw material in biopharmaceutical manufacturing. It serves as an ingredient, a cleaning agent, and a solvent in countless production steps. Its quality directly affects product safety, efficacy, and regulatory compliance. Pharmacopoeias around the world—including the Chinese Pharmacopoeia (ChP), the United States Pharmacopeia (USP), and the European Pharmacopoeia (Ph. Eur.)—have established comprehensive quality standards for pharmaceutical waters. Understanding these standards is essential for any biopharmaceutical facility.

Categories of Pharmaceutical Water

The Chinese Pharmacopoeia classifies pharmaceutical water into four grades, based on intended use and required purity. Drinking water is the starting material, typically meeting national tap water standards. Purified water is prepared from drinking water by methods such as distillation, ion exchange, or reverse osmosis. It is used in general drug preparation, equipment cleaning, and as feedwater for further purification. 

Water for injection is a higher-grade water, required to be free of bacterial endotoxins. It is used in sterile product manufacturing and preparations that come into direct contact with the bloodstream. Sterilised water for injection is Water for Injection that has been packaged and sterilised, used as a final rinse or as a solvent for sterile products.

Key Quality Parameters

Pharmacopoeias define water quality through a set of critical parameters. Conductivity measures the concentration of dissolved ions; lower conductivity indicates higher purity. Total Organic Carbon quantifies organic contamination; all pharmacopoeias set the same limit of 0.50 mg/L for both Purified Water and Water for Injection. Microbial limits are specified as colony-forming units per volume: Purified Water allows up to 100 CFU/mL, while Water for Injection permits no more than 10 CFU per 100 mL. Bacterial endotoxins are tested only for Water for Injection, with the limit set at less than 0.25 EU/mL.

The 2025 Chinese Pharmacopoeia: Three Major Revisions

The 2025 edition of the Chinese Pharmacopoeia, which took effect in October 2025, introduced significant changes to the pharmaceutical water standards. These revisions bring the ChP closer into alignment with the USP and Ph. Eur..

The first major change concerns the manufacturing method for Water for Injection. Previously, the ChP stipulated that Water for Injection must be produced by distillation. The 2025 revision now permits the use of purification processes "equivalent to distillation," such as reverse osmosis coupled with electro-deionisation. This provides manufacturers with greater flexibility in water system design and energy optimisation.

The second change involves the streamlining of analytical testing. Under the previous system, Purified Water required ten separate tests. The 2025 revision allows conductivity to serve as a surrogate for multiple chemical tests. When Purified Water meets the conductivity criteria specified for Water for Injection, it is exempted from testing for pH, heavy metals, nitrate, nitrite, and ammonia. Even when conductivity meets the Purified Water standard but not the WFI level, the number of required tests is reduced. This risk-based approach reduces redundant testing while maintaining quality assurance.